Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
26650 | 249 | 53.8 | 82% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
12 | 4 | POLYMER SCIENCE//MATERIALS SCIENCE, PAPER & WOOD//CHEMISTRY, PHYSICAL | 1084170 |
41 | 3 | INTERNATIONAL JOURNAL OF PHARMACEUTICS//DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY//PHARMACOLOGY & PHARMACY | 99449 |
147 | 2 | SOLID LIPID NANOPARTICLES//POLYMERIC MICELLES//LIPOSOMES | 23275 |
26650 | 1 | NANOART//PHARMACEUT NANOMAT SCI//PHARMACOL EXPT NEUROSCI | 249 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | NANOART | authKW | 858423 | 3% | 100% | 7 |
2 | PHARMACEUT NANOMAT SCI | address | 339589 | 2% | 46% | 6 |
3 | PHARMACOL EXPT NEUROSCI | address | 333238 | 17% | 6% | 42 |
4 | NANOFORMULATED ANTIRETROVIRAL THERAPY | authKW | 275920 | 1% | 75% | 3 |
5 | PEDIATRIC HIV AIDS PHARMACOTHERAPY | authKW | 275920 | 1% | 75% | 3 |
6 | GRP BIOMAT NANOTECHNOL IMPROVED MED BIONIMED | address | 275908 | 4% | 25% | 9 |
7 | ANTIRETROVIRAL DRUG TARGETING | authKW | 245264 | 1% | 100% | 2 |
8 | LIPID ASSOCIATED DRUG | authKW | 245264 | 1% | 100% | 2 |
9 | LONG ACTING NANOFORMULATED ANTIRETROVIRAL THERAPY | authKW | 245264 | 1% | 100% | 2 |
10 | LYMPHATIC DRUG INSUFFICIENCY | authKW | 245264 | 1% | 100% | 2 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 1545 | 46% | 0% | 115 |
2 | Nanoscience & Nanotechnology | 1099 | 23% | 0% | 57 |
3 | Virology | 335 | 9% | 0% | 23 |
4 | Materials Science, Biomaterials | 266 | 6% | 0% | 14 |
5 | Infectious Diseases | 248 | 10% | 0% | 25 |
6 | Medicine, Research & Experimental | 133 | 10% | 0% | 24 |
7 | Biotechnology & Applied Microbiology | 116 | 10% | 0% | 26 |
8 | Chemistry, Multidisciplinary | 55 | 12% | 0% | 31 |
9 | Immunology | 54 | 9% | 0% | 22 |
10 | Chemistry, Medicinal | 23 | 4% | 0% | 9 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PHARMACEUT NANOMAT SCI | 339589 | 2% | 46% | 6 |
2 | PHARMACOL EXPT NEUROSCI | 333238 | 17% | 6% | 42 |
3 | GRP BIOMAT NANOTECHNOL IMPROVED MED BIONIMED | 275908 | 4% | 25% | 9 |
4 | PERSONALIZED NANOMED IMMUNOL | 220735 | 1% | 60% | 3 |
5 | DRUG DELIVERY NANOMED | 160634 | 5% | 10% | 13 |
6 | ADMET PK BAC | 122632 | 0% | 100% | 1 |
7 | AICA S | 122632 | 0% | 100% | 1 |
8 | AU PK | 122632 | 0% | 100% | 1 |
9 | COUNCIL SCI IND MAT SCI MFG | 122632 | 0% | 100% | 1 |
10 | DRUG DELIVERY NANMED | 122632 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | NANOMEDICINE | 36339 | 8% | 2% | 19 |
2 | NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 6111 | 3% | 1% | 8 |
3 | INTERNATIONAL JOURNAL OF NANOMEDICINE | 4619 | 4% | 0% | 11 |
4 | EXPERT OPINION ON DRUG DELIVERY | 4114 | 2% | 1% | 6 |
5 | DRUG DELIVERY AND TRANSLATIONAL RESEARCH | 3698 | 1% | 1% | 3 |
6 | JOURNAL OF DRUG TARGETING | 2831 | 2% | 0% | 6 |
7 | CURRENT DRUG DELIVERY | 2368 | 1% | 1% | 3 |
8 | ADVANCED DRUG DELIVERY REVIEWS | 2239 | 3% | 0% | 7 |
9 | JOURNAL OF NEUROIMMUNE PHARMACOLOGY | 1783 | 1% | 0% | 3 |
10 | DRUG DELIVERY | 1506 | 2% | 0% | 4 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GIACALONE, G , HILLAIREAU, H , FATTAL, E , (2015) IMPROVING BIOAVAILABILITY AND BIODISTRIBUTION OF ANTI-HIV CHEMOTHERAPY.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 75. ISSUE . P. 40 -53 | 38 | 31% | 4 |
2 | MARTINEZ-SKINNER, AL , ARAINGA, MA , PULIGUJJA, P , PALANDRI, DL , BALDRIDGE, HM , EDAGWA, BJ , MCMILLAN, JM , MOSLEY, RL , GENDELMAN, HE , (2015) CELLULAR RESPONSES AND TISSUE DEPOTS FOR NANOFORMULATED ANTIRETROVIRAL THERAPY.PLOS ONE. VOL. 10. ISSUE 12. P. - | 25 | 44% | 1 |
3 | EDAGWA, BJ , ZHOU, T , MCMILLAN, JM , LIU, XM , GENDELMAN, HE , (2014) DEVELOPMENT OF HIV RESERVOIR TARGETED LONG ACTING NANOFORMULATED ANTIRETROVIRAL THERAPIES.CURRENT MEDICINAL CHEMISTRY. VOL. 21. ISSUE 36. P. 4186 -4198 | 36 | 29% | 8 |
4 | SHAO, JW , KRAFT, JC , LI, BW , YU, J , FREELING, J , KOEHN, J , HO, RJ , (2016) NANODRUG FORMULATIONS TO ENHANCE HIV DRUG EXPOSURE IN LYMPHOID TISSUES AND CELLS: CLINICAL SIGNIFICANCE AND POTENTIAL IMPACT ON TREATMENT AND ERADICATION OF HIV/AIDS.NANOMEDICINE. VOL. 11. ISSUE 5. P. 545 -564 | 28 | 34% | 1 |
5 | PARBOOSING, R , MAGUIRE, GEM , GOVENDER, P , KRUGER, HG , (2012) NANOTECHNOLOGY AND THE TREATMENT OF HIV INFECTION.VIRUSES-BASEL. VOL. 4. ISSUE 4. P. 488 -520 | 37 | 25% | 24 |
6 | DAS, MK , SARMA, A , CHAKRABORTY, T , (2016) NANO-ART AND NEUROAIDS.DRUG DELIVERY AND TRANSLATIONAL RESEARCH. VOL. 6. ISSUE 5. P. 452 -472 | 30 | 28% | 1 |
7 | KUMAR, L , VERMA, S , PRASAD, DN , BHARDWAJ, A , VAIDYA, B , JAIN, AK , (2015) NANOTECHNOLOGY: A MAGIC BULLET FOR HIV AIDS TREATMENT.ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY. VOL. 43. ISSUE 2. P. 71 -86 | 29 | 30% | 1 |
8 | PULIGUJJA, P , BALKUNDI, SS , KENDRICK, LM , BALDRIDGE, HM , HILAIRE, JR , BADE, AN , DASH, PK , ZHANG, G , POLUEKTOVA, LY , GORANTLA, S , ET AL (2015) PHARMACODYNAMICS OF LONG-ACTING FOLIC ACID-RECEPTOR TARGETED RITONAVIR-BOOSTED ATAZANAVIR NANOFORMULATIONS.BIOMATERIALS. VOL. 41. ISSUE . P. 141 -150 | 16 | 44% | 7 |
9 | MEHENDALE, R , JOSHI, M , PATRAVALE, V , (2013) NANOMEDICINES FOR TREATMENT OF VIRAL DISEASES.CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS. VOL. 30. ISSUE 1. P. 1 -49 | 33 | 22% | 8 |
10 | NAIR, M , JAYANT, RD , KAUSHIK, A , SAGAR, V , (2016) GETTING INTO THE BRAIN: POTENTIAL OF NANOTECHNOLOGY IN THE MANAGEMENT OF NEUROAIDS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 103. ISSUE . P. 202 -217 | 29 | 20% | 2 |
Classes with closest relation at Level 1 |